Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Iorio A, Stonebraker JS, Chambost H, et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med 2019; 171(8): 540–546. doi: 10.7326/M19-1208.IorioAStonebrakerJSChambostHData and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registriesAnn Intern Med2019171854054610.7326/M19-120831499529Open DOISearch in Google Scholar
Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of haemophilia A: a review. Biologics 2021; 15: 221–235. doi: 10.2147/BTT.S252580.MarchesiniEMorfiniMValentinoLRecent advances in the treatment of haemophilia A: a reviewBiologics20211522123510.2147/BTT.S252580821453934163136Open DOISearch in Google Scholar
Weyand AC, James PD. Sexism in the management of bleeding disorders. Res Pract Thromb Haemost 2020; 5(1): 51–54. doi: 10.1002/rth2.12468.WeyandACJamesPDSexism in the management of bleeding disordersRes Pract Thromb Haemost202051515410.1002/rth2.12468784507033537529Open DOISearch in Google Scholar
van Galen KPM, d'Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost 2021; 19(8): 1883–1887. doi: 10.1111/jth.15397.van GalenKPMd'OironRJamesPA new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTHJ Thromb Haemost20211981883188710.1111/jth.15397836171334327828Open DOISearch in Google Scholar
Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers 2021; 7(1): 45. doi: 10.1038/s41572-021-00278-x.BerntorpEFischerKHartDPHaemophiliaNat Rev Dis Primers2021714510.1038/s41572-021-00278-x34168126Open DOISearch in Google Scholar
Chen S-L. Economic costs of haemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 2016; 22(5 Suppl): s126–33.ChenS-LEconomic costs of haemophilia and the impact of prophylactic treatment on patient managementAm J Manag Care2016225 Suppls12633Search in Google Scholar
Gualtierotti R, Tafuri F, Arcudi S, et al. Current and emerging approaches for pain management in hemophilic arthropathy. Pain Ther 2022; 11(1): 1–15. doi: 10.1007/s40122-021-00345-x.GualtierottiRTafuriFArcudiSCurrent and emerging approaches for pain management in hemophilic arthropathyPain Ther202211111510.1007/s40122-021-00345-x886124335020184Open DOISearch in Google Scholar
Barry V, Buckner TW, Lynch ME, et al. An evaluation of PROMIS health domains in adults with haemophilia: A cross-sectional study. Haemophilia 2021; 27(3): 375–382. doi: 10.1111/hae.14321.BarryVBucknerTWLynchMEAn evaluation of PROMIS health domains in adults with haemophilia: A cross-sectional studyHaemophilia202127337538210.1111/hae.1432133866654Open DOISearch in Google Scholar
DeKoven M, Karkare S, Kelley LA, et al. Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States. Haemophilia 2014; 20(4): 541–9. doi: 10.1111/hae.12379.DeKovenMKarkareSKelleyLAUnderstanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United StatesHaemophilia2014204541910.1111/hae.1237924472032Open DOISearch in Google Scholar
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: 10.1056/NEJMoa1703068.OldenburgJMahlanguJNKimBEmicizumab prophylaxis in hemophilia A with inhibitorsN Engl J Med2017377980981810.1056/NEJMoa170306828691557Open DOISearch in Google Scholar
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: 10.1056/NEJMoa1803550.MahlanguJOldenburgJPaz-PrielIEmicizumab prophylaxis in patients who have hemophilia A without inhibitorsN Engl J Med2018379981182210.1056/NEJMoa180355030157389Open DOISearch in Google Scholar
Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program 2021; 2021(1): 219–225. doi: 10.1182/hematology.2021000253.EllsworthPMaAFactor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?Hematology Am Soc Hematol Educ Program20212021121922510.1182/hematology.2021000253879112334889356Open DOISearch in Google Scholar
McGill JR, Simhadri VL, Sauna ZE. HLA Variants and inhibitor development in hemophilia A: a retrospective case-controlled study using the ATHN dataset. Front Med (Lausanne) 2021; 8: 663396. doi: 10.3389/fmed.2021.663396.McGillJRSimhadriVLSaunaZEHLA Variants and inhibitor development in hemophilia A: a retrospective case-controlled study using the ATHN datasetFront Med (Lausanne)2021866339610.3389/fmed.2021.663396813940534026790Open DOISearch in Google Scholar
Male C, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 2021; 106(1): 123–129. doi: 10.3324/haematol.2019.239160.MaleCAnderssonNGRafowiczAInhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studyHaematologica2021106112312910.3324/haematol.2019.239160777624631919092Open DOISearch in Google Scholar
Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia a. Thromb Res 2018; 168: 20–27. doi: 10.1016/j.thromres.2018.05.027.GaragiolaIPallaRPeyvandiFRisk factors for inhibitor development in severe hemophilia aThromb Res2018168202710.1016/j.thromres.2018.05.02729879570Open DOISearch in Google Scholar
Valentino LA, Kempton CL, Kruse-Jarres R, et al.; International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia 2015; 21(5): 559–67. doi: 10.1111/hae.12730.ValentinoLAKemptonCLKruse-JarresRInternational Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitorsHaemophilia20152155596710.1111/hae.1273026032231Open DOISearch in Google Scholar
Davis JA, Klamroth R, Benchikh El Fegoun S, Habis R, de Moerloose P. A survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in nonhaemophilia treatment centres. Haemophilia 2020; 26(4): e205–e208. doi: 10.1111/hae.13983.DavisJAKlamrothRBenchikh El FegounSHabisRde MoerloosePA survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in nonhaemophilia treatment centresHaemophilia2020264e205e20810.1111/hae.1398332267042Open DOISearch in Google Scholar
Valentino LA, Baker JR, Butler R, et al. Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders. J Blood Med 2021; 12: 897–911. doi: 10.2147/JBM.S325031.ValentinoLABakerJRButlerRIntegrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disordersJ Blood Med20211289791110.2147/JBM.S325031854426534707421Open DOISearch in Google Scholar
World Medical Association. WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/ (accessed 21 November 2022).World Medical AssociationWMA Declaration of Helsinki – Ethical principles for medical research involving human subjectsAvailable at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/ (accessed 21 November 2022).Search in Google Scholar
Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12(11): 1935–9. doi: 10.1111/jth.12672.BlanchetteVSKeyNSLjungLRManco-JohnsonMJvan den BergHMSrivastavaASubcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTHJ Thromb Haemost201412111935910.1111/jth.1267225059285Open DOISearch in Google Scholar
Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 Suppl 2: S22–5. doi: 10.1016/S0049-3848(10)70150-X.MakrisMCalizzaniGFischerKEUHASS: The European Haemophilia Safety Surveillance systemThromb Res2011127Suppl 2S22510.1016/S0049-3848(10)70150-X21193110Open DOISearch in Google Scholar
Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia 2018; 24(3): 487–491. doi: 10.1111/hae.13435.BoylanBMillerCHEffects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levelsHaemophilia201824348749110.1111/hae.13435607256529461004Open DOISearch in Google Scholar